Literature DB >> 17723123

Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients.

R Paniccia1, E Antonucci, A M Gori, R Marcucci, C Giglioli, D Antoniucci, G F Gensini, R Abbate, D Prisco.   

Abstract

BACKGROUND: Two point-of-care (POC) systems have been recently proposed as rapid tools with which to evaluate residual platelet reactivity (RPR) in coronary artery disease (CAD) patients. OBJECTIVES AND METHODS: We compared Platelet Function Analyzer-100 (PFA-100) closure times (CTs) by collagen/adenosine 5'-diphosphate (ADP) (C/ADP CT) cartridge and the VerifyNow P2Y12 Assay (VerifyNow) with light transmission aggregation (LTA) induced by 2 and 10 micromol L(-1) ADP in 1267 CAD patients on dual antiplatelet therapy who underwent percutaneous coronary intervention. We also performed the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay by cytofluorimetric analysis in a subgroup of 115 patients.
RESULTS: Cut-off values for identifying RPR were: > or = 54% and > or = 66% for LTA induced by 2 and 10 micromol L(-1) ADP respectively, and > or = 264 P2Y12 Reaction Units (PRU) for VerifyNow. The cut-off for PFA-100 C/ADP CT was > or = 68 s. RPR was detected in 25.1% of patients by 2 mumol L(-1) ADP-induced LTA (ADP-LTA), in 23.2% by 10 micromol L(-1) ADP-LTA, in 24.4% by PFA-100, and in 24.7% by VerifyNow. PFA-100 results did not parallel those obtained with LTA. VerifyNow showed a significant correlation (rho = 0.62, P < 0.001) and significant agreement (k = 0.34, P < 0.001) with LTA induced by 2 micromol L(-1) ADP. The correlation was similar but the agreement was better between VerifyNow and 10 micromol L(-1) ADP-LTA (rho = 0.64, P < 0.0001; k = 0.43, P < 0.001). Significant relationships were found between VASP platelet reactivity index and both ADP-LTA and VerifyNow. PFA-100 C/ADP CT did not significantly correlate with any of the other assays.
CONCLUSIONS: Our results show a significant correlation between LTA and VerifyNow but not the PFA-100 C/ADP assay. Clinical validation studies for POC systems are necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17723123     DOI: 10.1111/j.1538-7836.2007.02656.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  26 in total

1.  Optimal timing of clopidogrel discontinuation in Japanese patients: platelet aggregation test using the VerifyNow® system.

Authors:  Hiroki Takiuchi; Kazuo Tanemoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-08-23

Review 2.  Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?

Authors:  Diana A Gorog; Joseph M Sweeny; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2009-04-14       Impact factor: 32.419

3.  Antiplatelet therapy: Personalized medicine for clopidogrel resistance?

Authors:  Jean-Sébastien Hulot; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2009-05       Impact factor: 32.419

Review 4.  Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.

Authors:  Nalyaka Sambu; Nick Curzen
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

5.  Aspirin resistance: Fact or fiction? A point of view.

Authors:  Jawahar L Mehta; Bhavna Mohandas
Journal:  World J Cardiol       Date:  2010-09-26

6.  Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications.

Authors:  H-S Kang; B J Kwon; J E Kim; Moon Hee Han
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-11       Impact factor: 3.825

Review 7.  Platelet function monitoring and clopidogrel.

Authors:  Andrew R Harper; Matthew J Price
Journal:  Curr Cardiol Rep       Date:  2013-01       Impact factor: 2.931

Review 8.  Gender and anti-thrombotic therapy: from biology to clinical implications.

Authors:  Rossella Marcucci; Gabriele Cioni; Betti Giusti; Cinzia Fatini; Lorenza Rossi; Maddalena Pazzi; Rosanna Abbate
Journal:  J Cardiovasc Transl Res       Date:  2014-01-28       Impact factor: 4.132

Review 9.  Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.

Authors:  Rakesh K Sharma; Hanumanth K Reddy; Vibhuti N Singh; Rohit Sharma; Donald J Voelker; Girish Bhatt
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

10.  The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p(2)y(12) assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation.

Authors:  Kyounghoon Lee; Seung-Whan Lee; Jun-Won Lee; Seong-Yoon Kim; Young-Jin Youn; Min-Soo Ahn; Jang-Young Kim; Byung-Su Yoo; Junghan Yoon; Kyung-Hoon Choe
Journal:  Korean Circ J       Date:  2009-12-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.